PharVision Advisers’s Fabrinet FN Stock Holding History

PharVision Advisers’s Portfolio FN Stock Details FN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,023	Closed	-$466K	–	306
2025 Q4	$466K	Buy	+1,023	New	+$445K	0.24%	55
2025 Q1	–	Sell	-1,003	Closed	-$221K	–	355
2024 Q4	$221K	Buy	+1,003	New	+$242K	0.19%	262

Other funds holding FN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

PharVision Advisers's FN Position: Q1 2026 in Review

PharVision Advisers sold out of Fabrinet (FN) in Q1 2026, closing a stake of 1,023 shares — an estimated $466K sold.

PharVision Advisers first reported a position in FN in Q4 2024 and held it in 2 quarters. The position peaked at $466K in Q4 2025. 669 funds tracked by Wall St. Rank hold FN as of Q1 2026.

PharVision Advisers reported no remaining Fabrinet position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 1,023 Fabrinet shares in Q1 2026, an estimated $466K.
PharVision Advisers first reported a position in Fabrinet in Q4 2024 and held it in 2 quarters.
PharVision Advisers's Fabrinet position peaked at $466K in Q4 2025.
669 funds tracked by Wall St. Rank held Fabrinet as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.